Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated January 16, 2026, details a series of material definitive agreements entered into by Jaguar Health, Inc. The company executed privately negotiated exchange transactions with two existing investors, Iliad Research and Trading, L.P. ("Iliad") and Streeterville Capital, LLC ("Streeterville"). The primary objective of these transactions was to reduce outstanding royalty obligations and retire preferred stock by issuing pre-funded common stock purchase warrants.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial metrics such as revenue, net income, operating cash flow, or total debt balances. Instead, it reports specific capital structure adjustments:
- Royalty Interest Reductions:
- Iliad: $1,187,914.07 reduction in the October 2020 Royalty Interest.
- Streeterville: $850,000 reduction in the August 2022 Royalty Interest.
- Preferred Stock Retirements:
- Series L Preferred Stock: 22 shares (Iliad) and 99.3822 shares (Streeterville) were cancelled and retired.
- Series M Preferred Stock: 87.78 shares (Iliad) and 69.44 shares (Streeterville) were cancelled and retired.
- Equity Issuance (Pre-Funded Warrants):
- Total warrants issued: 9,576,281 shares of Common Stock.
- Exercise Price: $0.001 per share.
- Breakdown: 1,553,844 (Iliad Royalty), 1,111,837 (Streeterville Royalty), 719,424 (Iliad Series L), 3,249,908 (Streeterville Series L), 2,870,503 (Iliad Series M), and 2,270,765 (Streeterville Series M).
Material Changes Versus Prior Period
The filing does not present comparative financial data against a prior period. The material change is the structural alteration of the company's liabilities and equity:
- Reduction of specific royalty debt obligations totaling approximately $2.04 million.
- Elimination of specific tranches of Series L and Series M Perpetual Preferred Stock.
- Issuance of unregistered equity securities (pre-funded warrants) in exchange for the aforementioned debt and preferred stock retirements.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future business performance. Key terms and risks associated with the transaction include:
- Beneficial Ownership Limitation: The Pre-Funded Warrants are subject to a limitation ensuring that, upon exercise, the holder's beneficial ownership (including affiliates) does not exceed 9.99% of the total outstanding Common Stock.
- Exemption Reliance: The securities were issued in reliance on the exemption from registration provided under Section 3(a)(9) of the Securities Act of 1933.
- Immediate Exercisability: The warrants are exercisable in part or in full immediately.
Investor Verification Checklist
- Verify the updated total outstanding balance of the October 2020 and August 2022 Royalty Interests following the reductions.
- Confirm the total number of Common Stock shares outstanding post-transaction to assess the dilution impact of the 9,576,281 pre-funded warrants.
- Review the attached Exhibits (4.1, 10.1 through 10.6) for specific covenants, representations, and warranties not detailed in the summary.
- Check subsequent filings for the actual exercise of these warrants and the resulting cash inflow (if any) or further equity issuance.